Stock listing
NASDAQ:VBIO Valion Bio, Inc. Stock
Home listing (NASDAQ) of Valion Bio, Inc.
Follow Valion Bio, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:VBIO
$0.481 USD -0.022 (-4.3%)
Close on Nov 20, 2026
- Day range
- $0.480 – $0.547 USDNov 20, 2026
- Volume
- 135,203 sharesNov 20, 2026
- Market cap
- $1.04M USDAt the close on Nov 20, 2026 · price × 2.16M shares outstanding
- 52-week range
- $0.473 – $67.500 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $3.73M USDMedian day 139,300 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:VBIO · Home | $0.481 USD | -0.022 (-4.3%) | 135,203 | $0.540 | $0.547 | $0.480 | $0.502 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:VBIO · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.481 | -0.022 | -4.3% | $0.540 | $0.547 | $0.480 | 135,203 | |
| $0.502 | -0.041 | -7.5% | $0.559 | $0.559 | $0.484 | 105,521 | |
| $0.543 | +0.014 | +2.7% | $0.562 | $0.598 | $0.500 | 1,188,067 | |
| $0.529 | 0.000 | -0.1% | $0.540 | $0.540 | $0.505 | 114,483 | |
| $0.529 | +0.021 | +4.1% | $0.492 | $0.548 | $0.480 | 100,089 | |
| $0.509 | +0.006 | +1.2% | $0.507 | $0.516 | $0.491 | 82,648 | |
| $0.503 | -0.026 | -4.9% | $0.523 | $0.536 | $0.493 | 58,767 | |
| $0.529 | -0.013 | -2.3% | $0.545 | $0.545 | $0.501 | 46,850 | |
| $0.542 | +0.032 | +6.2% | $0.510 | $0.568 | $0.510 | 118,023 | |
| $0.510 | +0.008 | +1.6% | $0.488 | $0.510 | $0.481 | 99,173 | |
| $0.502 | -0.015 | -2.9% | $0.520 | $0.520 | $0.473 | 111,521 | |
| $0.517 | -0.014 | -2.6% | $0.540 | $0.540 | $0.500 | 93,037 | |
| $0.531 | 0.000 | 0.0% | $0.530 | $0.563 | $0.505 | 55,898 | |
| $0.531 | -0.019 | -3.5% | $0.584 | $0.584 | $0.516 | 97,556 | |
| $0.550 | -0.067 | -10.8% | $0.600 | $0.603 | $0.524 | 216,589 | |
| $0.617 | -0.062 | -9.1% | $0.650 | $0.702 | $0.616 | 138,048 | |
| $0.679 | -0.103 | -13.2% | $0.763 | $0.770 | $0.663 | 525,562 | |
| $0.782 | -0.058 | -6.9% | $0.752 | $0.870 | $0.750 | 316,249 | |
| $0.840 | -0.100 | -10.6% | $0.880 | $0.890 | $0.680 | 17,366,069 | |
| $0.940 | -0.016 | -1.7% | $0.910 | $0.956 | $0.900 | 41,700 | |
| $0.956 | -0.164 | -14.6% | $1.100 | $1.100 | $0.931 | 173,600 | |
| $1.120 | -0.070 | -5.9% | $1.200 | $1.200 | $1.100 | 201,700 | |
| $1.190 | +0.030 | +2.6% | $1.120 | $1.260 | $1.110 | 59,400 | |
| $1.160 | -0.010 | -0.9% | $1.110 | $1.200 | $1.045 | 130,100 | |
| $1.170 | -0.060 | -4.9% | $1.230 | $1.240 | $1.130 | 270,600 | |
| $1.230 | -0.220 | -15.2% | $1.110 | $1.330 | $1.110 | 13,726,600 | |
| $1.450 | -0.100 | -6.5% | $1.540 | $1.550 | $1.435 | 160,100 | |
| $1.550 | -0.130 | -7.7% | $1.680 | $1.680 | $1.470 | 179,200 | |
| $1.680 | -0.460 | -21.5% | $2.100 | $2.140 | $1.590 | 248,600 | |
| $2.140 | -0.070 | -3.2% | $2.190 | $2.270 | $2.100 | 140,000 | |
| $2.210 | +0.020 | +0.9% | $2.070 | $2.280 | $2.070 | 150,900 | |
| $2.190 | -0.190 | -8.0% | $2.310 | $2.380 | $2.180 | 125,500 | |
| $2.380 | -0.100 | -4.0% | $2.360 | $2.480 | $2.330 | 128,300 | |
| $2.480 | -0.110 | -4.2% | $2.420 | $2.490 | $2.300 | 309,800 | |
| $2.590 | +0.080 | +3.2% | $2.550 | $2.690 | $2.456 | 237,600 | |
| $2.510 | -0.290 | -10.4% | $2.550 | $2.750 | $2.480 | 674,700 | |
| $2.800 | -0.030 | -1.1% | $4.000 | $4.390 | $2.530 | 52,286,800 | |
| $2.830 | +0.130 | +4.8% | $2.630 | $3.118 | $2.410 | 376,600 | |
| $2.700 | -0.330 | -10.9% | $2.820 | $3.030 | $2.650 | 219,900 | |
| $3.030 | -0.450 | -12.9% | $3.340 | $3.499 | $2.790 | 751,800 | |
| $3.480 | +0.750 | +27.5% | $2.620 | $3.790 | $2.320 | 10,751,400 | |
| $2.730 | +0.240 | +9.6% | $2.450 | $3.290 | $2.254 | 2,109,200 | |
| $2.490 | +0.110 | +4.6% | $2.410 | $2.800 | $2.360 | 536,100 | |
| $2.380 | +0.260 | +12.3% | $2.138 | $2.450 | $2.133 | 122,700 | |
| $2.120 | -0.110 | -4.9% | $2.290 | $2.360 | $2.120 | 56,900 | |
| $2.230 | +0.150 | +7.2% | $2.160 | $2.440 | $2.120 | 216,400 | |
| $2.080 | -0.030 | -1.4% | $2.050 | $2.260 | $2.050 | 114,700 | |
| $2.110 | +0.010 | +0.5% | $2.120 | $2.170 | $2.059 | 33,900 | |
| $2.100 | -0.160 | -7.1% | $2.250 | $2.420 | $2.100 | 146,600 | |
| $2.260 | +0.060 | +2.7% | $2.190 | $2.390 | $2.170 | 161,000 | |
| $2.200 | -0.200 | -8.3% | $2.380 | $2.380 | $2.158 | 76,500 | |
| $2.400 | -0.100 | -4.0% | $2.260 | $2.470 | $2.220 | 122,100 | |
| $2.500 | -0.270 | -9.7% | $2.740 | $2.740 | $2.440 | 159,500 | |
| $2.770 | -0.030 | -1.1% | $2.900 | $2.989 | $2.720 | 71,500 | |
| $2.800 | -0.320 | -10.3% | $3.030 | $3.210 | $2.750 | 139,300 | |
| $3.120 | +0.050 | +1.6% | $3.020 | $3.239 | $2.700 | 148,200 | |
| $3.070 | -0.500 | -14.0% | $3.220 | $3.460 | $2.880 | 291,900 | |
| $3.570 | +0.545 | +18.0% | $2.800 | $3.870 | $2.800 | 663,100 | |
| $3.025 | -0.050 | -1.6% | $3.075 | $3.350 | $2.925 | 20,899 | |
| $3.075 | -0.825 | -21.2% | $3.800 | $3.875 | $2.925 | 13,009 | |
| $3.900 | -0.075 | -1.9% | $3.850 | $4.125 | $3.825 | 5,642 | |
| $3.975 | -0.175 | -4.2% | $3.625 | $4.075 | $3.500 | 11,678 | |
| $4.150 | +1.075 | +35.0% | $3.000 | $4.700 | $2.925 | 175,607 | |
| $3.075 | +0.025 | +0.8% | $2.975 | $3.300 | $2.800 | 6,250 | |
| $3.050 | -0.300 | -9.0% | $3.325 | $3.325 | $2.875 | 7,999 |
Splits
3 splits since 2023 · NASDAQ:VBIO · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-25 | Consolidation | |
| 1-for-17 | Consolidation | |
| 1-for-100 | Consolidation |
- Ticker
- NASDAQ:VBIO
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 19, 2026
Valion Bio Welcomes Former U.S. Army Regulatory Leader and Biotech CEO Dr. Armand Balboni as Advisor in Run-up to Entolimod Therapeutic Efficacy Data Readout
Latest earnings call · May 14, 2026
Valion Bio (NASDAQ:VBIO) Q1 2026 Earnings Call
Replay and transcript
Latest deck · Jan 20, 2026
Tivic Health Systems — Investor Presentation (January 2026)
Investor deck · 18 slides
Latest news
Valion Bio Welcomes Former U.S. Army Regulatory Leader and Biotech CEO Dr. Armand Balboni as Advisor in Run-up to Entolimod Therapeutic Efficacy Data Readout
Nov 19, 2026
Closed $0.481 (-4.3%) on Nov 20, 2026
Valion Bio Reports Completion of 200-Liter Entolimod Production Run; Material Supplying Ongoing AFRRI Study
Nov 17, 2026
Closed $0.543 (+2.7%) on Nov 17, 2026
Valion Bio Reinforces Commitment to American Troops; Discusses Entolimod with Attendees at RW Baird's National Security Conference
Nov 11, 2026
Closed $0.503 (-4.9%) on Nov 11, 2026
Valion Bio Advancing Entolimod into U.S. Government-Funded Therapeutic Efficacy Study Following Positive Safety Results
Oct 30, 2026
Closed $0.55 (-10.8%) on Oct 30, 2026
Valion Bio Announces Positive Safety Results From U.S. Government-Funded Entolimod Study, Paving Way For Therapeutic Efficacy Evaluation
Oct 28, 2026
Closed $0.679 (-13.2%) on Oct 28, 2026
Valion Bio Receives Unsolicited Acquisition Interest in Velocity Bioworks; Weighs Strategic Options
Oct 26, 2026
Closed $0.84 (-10.6%) on Oct 26, 2026
Valion Bio's New Leadership Unveils 30-Day Agenda to Accelerate Clinical Pipeline and Unlock Shareholder Value
Oct 21, 2026
Closed $1.12 (-5.9%) on Oct 21, 2026
Valion Bio's Next-Generation NMR Partnership with LarmorBio Delivers Initial Feasibility Milestone
Oct 15, 2026
Closed $1.23 (-15.2%) on Oct 15, 2026
With Section 232 Tariffs Reshaping Biotech, Valion Bio's Velocity Bioworks Capitalizes on Domestic CDMO Surge
Oct 14, 2026
Closed $1.45 (-6.5%) on Oct 14, 2026
Valion Appoints Life Sciences Veteran Dean Zikria as Interim CEO and Announces Board Leadership Transitions
Sep 23, 2026
Closed $2.73 (+9.6%) on Sep 23, 2026
Valion Bio, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 27 in the last 12 months · 27 in all · newest Nov 19, 2026 · oldest 2026
- Calls
- 16 calls with a replay · 16 with a transcript · latest May 14, 2026
- Decks
- 10 decks · latest Jan 20, 2026
Where Valion Bio, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:VBIO · Home listing · This page | NASDAQ | United States | USD |
| BOATS:VBIO | BOATS | United States | USD |
Valuation
EV/sales 42.8× against a median of −4.2×: the highest of 3 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $16.34M USD
- P/E
- Loss
- EV/sales
- 42.8×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.2×
- Gross margin
- 8.4%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 4.1×
- Beta vs S&P 500
- 1.11
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Valion Bio, Inc. · NASDAQ:VBIO | US$1.04M | US$16.34M | n/a | 42.8× | n/a | 0.2× | n/a | 4.1× | 1.11 |
| Agentix Corp. · OTC:AGTX | US$1.35M | US$1.34M | n/a | n/a | n/a | n/a | n/a | n/a | -0.73 |
| Clearmind Medicine Inc. · NASDAQ:CMND | US$1.33M | −US$9.01M | n/a | n/a | n/a | 0.2× | n/a | 0.0× | 0.29 |
| Artelo Biosciences, Inc. · NASDAQ:ARTL | US$1.30M | US$1.34M | n/a | n/a | n/a | 0.2× | n/a | 0.0× | 1.36 |
| International Stem Cell Corporation · OTC:ISCO | US$1.28M | −US$18.76M | 0.1× | −2.0× | n/a | 0.1× | 222.6% | 0.0× | -0.52 |
| SureNano Science Ltd · CSE:SURE | US$1.17M | US$672,321 | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 0.25 |
| GeoVax Labs, Inc. · NASDAQ:GOVX | US$985,460 | −US$915,033 | n/a | n/a | n/a | 0.9× | n/a | 0.2× | 1.47 |
| Biodexa Pharmaceuticals plc · NASDAQ:BDRX | US$982,950 | −US$3.22M | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 1.01 |
| Gabather AB · OMXSTO:GABA | US$919,514 | US$559,105 | n/a | n/a | n/a | 6.4× | n/a | 0.0× | n/a |
| ExpreS2ion Biotech Holding AB · OMXSTO:EXPRS2 | US$792,634 | −US$2.43M | n/a | −6.5× | n/a | 0.2× | −935.9% | 0.0× | n/a |
| Silexion Therapeutics Corp · NASDAQ:SLXN | US$790,001 | −US$3.60M | n/a | n/a | n/a | 0.3× | n/a | 0.1× | 2.77 |
| Median of the others | US$1.08M | −US$1.67M | 0.1× | −4.2× | 0.2× | −356.6% | 0.0× | 0.65 |
Team and board
Officers
| Officer | Role |
|---|---|
| Dean Zikria | Interim CEO, Director |
| Lisa Wolf | Chief Operating Officer & Chief Financial Officer |
| Melinda Lackey | General Counsel and SVP of Legal |
| Anna Szymanska | SVP, Quality and Regulatory Compliance |
| Brian W. O'Mara | VP, Process Sciences and Manufacturing |
Board
| Director | Role |
|---|---|
| Jared Malbin | Chair of the Board's Audit Committee, Independent Director |
| Christina Valauri | Independent Director |
| Dean Zikria | Interim CEO, Director |
| Michael K. Handley | Director |
| Thomas Jensen | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Valion Bio (NASDAQ:VBIO) Q1 2026 Earnings Call | Thu, May 14, 2026 · 5:00 PM ET | Replay |
| Tivic Health Systems, Inc. (TIVC) Q4 2025 Earnings Call | Wed, Mar 25, 2026 · 4:30 PM ET | Replay |
| Tivic Health Systems, Inc. (TIVC) Q3 2025 Earnings Call | Fri, Nov 14, 2025 · 4:30 PM ET | Replay |
| Tivic Health Systems, Inc. (TIVC) Q2 2025 Earnings Call | Thu, Aug 14, 2025 · 4:30 PM ET | Replay |
| Tivic Health Systems, Inc. (TIVC) Q1 2025 Earnings Call | Thu, May 15, 2025 · 4:30 PM ET | Replay |
| Tivic Health Systems, Inc. (TIVC) Q4 2024 Earnings Call | Fri, Mar 21, 2025 · 4:30 PM ET | Replay |
| Tivic Health Systems, Inc. (TIVC) Q3 2024 Earnings Call | Thu, Nov 14, 2024 · 4:30 PM ET | Replay |
| Tivic Health Systems, Inc. (TIVC) Q1 2024 Earnings Call | Wed, May 15, 2024 · 4:30 PM ET | Replay |
| Tivic Health Systems, Inc. (TIVC) Q4 2023 Earnings Call | Mon, Mar 25, 2024 · 4:30 PM ET | Replay |
| Tivic Health Systems, Inc. (TIVC) Q3 2023 Earnings Call | Tue, Nov 14, 2023 · 4:30 PM ET | Replay |
All 16 calls
| Call | When | Status |
|---|---|---|
| Tivic Health Systems, Inc. (TIVC) Q2 2023 Earnings Call | Mon, Aug 14, 2023 · 4:30 PM ET | Replay |
| Tivic Health Systems, Inc. (TIVC) Q1 2023 Earnings Call | Mon, May 15, 2023 · 4:30 PM ET | Replay |
| Tivic Health Systems, Inc. (TIVC) Q4 2022 Earnings Call | Fri, Mar 31, 2023 · 4:30 PM ET | Replay |
| Tivic Health Systems, Inc. (TIVC) Q3 2022 Earnings Call | Mon, Nov 14, 2022 · 4:30 PM ET | Replay |
| Tivic Health Systems, Inc. (TIVC) Q2 2022 Earnings Call | Mon, Aug 15, 2022 · 4:30 PM ET | Replay |
| Tivic Health Systems, Inc. (TIVC) Q1 2022 Earnings Call | Mon, May 16, 2022 · 4:30 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2026 | Nov 20, 2026 | |
| Q2 2026 | Aug 14, 2026 | +7.0% |
| Q1 2026 | May 15, 2026 | −7.6% |
| Q3 2025 | Nov 17, 2025 | −1.6% |
| Q2 2025 | Aug 15, 2025 | −5.4% |
| Q1 2025 | May 15, 2025 | −1.2% |
| Q4 2024 | Mar 24, 2025 | −9.6% |
| Q3 2024 | Nov 15, 2024 | −27.8% |
| Q2 2024 | Aug 15, 2024 | +6.1% |
| Q1 2024 | May 16, 2024 | −6.4% |
All 18 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2023 | Mar 26, 2024 | −17.9% |
| Q3 2023 | Nov 14, 2023 · After close | −13.8% |
| Q2 2023 | Aug 14, 2023 · After close | −7.5% |
| Q1 2023 | May 16, 2023 | −32.6% |
| Q4 2022 | Mar 31, 2023 · Before open | −13.2% |
| Q3 2022 | Nov 14, 2022 · Before open | 0.0% |
| Q2 2022 | Aug 15, 2022 · After close | −3.9% |
| Q1 2022 | Jun 1, 2022 | +7.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Tivic Health Systems — Investor Presentation (January 2026) | Investor deck | 18 slides | Jan 20, 2026 |
| Tivic Health Systems — Q1 2025 Earnings Presentation | Earnings | 16 slides | May 15, 2025 |
| Tivic Health Systems — Investor Presentation (March 2025) | Investor deck | 11 slides | Mar 21, 2025 |
| Tivic Health Systems — Investor Presentation (May 2024) | Investor deck | 19 slides | May 22, 2024 |
| Tivic Health Systems — Investor Presentation (March 2023) | Investor deck | 24 slides | Mar 31, 2023 |
| Tivic Health Systems — Investor Presentation (December 2022) | Investor deck | 24 slides | Dec 21, 2022 |
| Tivic Health Systems — Investor Presentation (October 2022) | Investor deck | 22 slides | Oct 26, 2022 |
| Tivic Health Systems — Investor Presentation (October 2022) | Investor deck | 24 slides | Oct 17, 2022 |
| Tivic Health Systems — Investor Presentation (April 2022) | Investor deck | 24 slides | Apr 18, 2022 |
| Tivic Health Systems — Investor Presentation (December 2021) | Investor deck | 24 slides | Dec 8, 2021 |
IPO
Went public as Tivic Health Systems, Inc. Priced at US$5.00 a share on Nov 10, 2021.
- Price
- US$5.00 a share
- Shares offered
- 3,000,000 shares of common stock
- Offering size
- US$15 million
- Underwriters' option
- Up to 450,000 more shares
- Listing
- TIVC on the Nasdaq Capital Market
- Underwriter
- ThinkEquity
- Shares delivered
- On or about Nov 15, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | May 14, 2021 |
| Filed publicly | Aug 3, 2021 |
| Amended 4 times | Newest Oct 29, 2021 |
| Shares registered with an exchange | Nov 10, 2021 |
| Declared effective by the SEC | Nov 10, 2021 |
| Final prospectus, with the price | Nov 12, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Nov 12, 2021 |
| EFFECT · Notice that a registration is effective | Nov 10, 2021 |
| CERT · Exchange's certificate of listing | Nov 10, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Nov 10, 2021 |
| CORRESP · Letter to the SEC | Nov 5, 2021 |
| CORRESP · Letter to the SEC | Nov 5, 2021 |
| S-1/A · Registration statement, amended | Oct 29, 2021 |
| CORRESP · Letter to the SEC | Sep 23, 2021 |
| S-1/A · Registration statement, amended | Sep 23, 2021 |
| UPLOAD · Letter from the SEC | Sep 20, 2021 |
All 23 filings
| Filing | Filed |
|---|---|
| S-1/A · Registration statement, amended | Sep 9, 2021 |
| CORRESP · Letter to the SEC | Sep 9, 2021 |
| UPLOAD · Letter from the SEC | Aug 18, 2021 |
| CORRESP · Letter to the SEC | Aug 12, 2021 |
| S-1/A · Registration statement, amended | Aug 12, 2021 |
| UPLOAD · Letter from the SEC | Aug 11, 2021 |
| CORRESP · Letter to the SEC | Aug 3, 2021 |
| S-1 · Registration statement | Aug 3, 2021 |
| UPLOAD · Letter from the SEC | Jul 9, 2021 |
| DRS/A · Draft registration statement, amended | Jul 2, 2021 |
| DRSLTR · Letter to the SEC with a draft | Jul 2, 2021 |
| UPLOAD · Letter from the SEC | Jun 14, 2021 |
| DRS · Draft registration statement | May 14, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Nov 12, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 382.0K | 780.0K | 1.18M | 1.84M | 1.26M | 860.0K | 420.0K | 102.4K | 163.4K | 248.3K |
| Cost of revenue | 350.0K | 778.0K | 889.0K | 1.54M | 1.29M | 1.09M | 713.0K | 77.9K | 108.3K | 149.5K |
| Gross profit | 32.0K | 2.00K | 287.0K | 299.0K | -38.0K | -233.0K | -293.0K | 24.5K | 55.1K | 98.9K |
| Research and development | 3.13M | 1.31M | 1.66M | 1.73M | 878.0K | 768.0K | 986.0K | 1.90M | 894.0K | 613.1K |
| Selling, general and administrative | 4.77M | 3.16M | 4.75M | 5.88M | 1.93M | 2.68M | 2.52M | 2.63M | 2.23M | |
| Operating income | -7.90M | -4.48M | -8.24M | -10.1M | -5.63M | -3.32M | -3.64M | -4.40M | -3.47M | -2.74M |
| Depreciation and amortization | 5.00K | 3.00K | 8.00K | 10.0K | 8.00K | 8.00K | 4.00K | 87.8K | 1.75M | 2.60M |
| EBITDA | -7.89M | -4.47M | -8.24M | -10.1M | -5.63M | -3.31M | -3.64M | -4.31M | -1.72M | -141.0K |
| Interest expense | 146.0K | 0 | 1.82M | 423.0K | 443.0K | 1.01K | 363 | |||
| Income before tax | 8.90M | 5.70M | -8.24M | -10.1M | -8.49M | -3.64M | -4.15M | -4.31M | -5.22M | -141.3K |
| Income tax | 0 | 0 | 2.00K | |||||||
| Net income | -8.88M | -5.66M | -8.24M | -10.1M | -8.49M | -3.64M | -4.15M | -4.31M | -5.22M | -141.3K |
| Earnings per share, basic | -7.84 | -19.68 | -176.80 | -104.32 | -2.43 | -667.71 | -761.10 | -0.19 | -0.38 | -0.02 |
| Earnings per share, diluted | -19.68 | -176.80 | -104.32 | -2.43 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 12.6M | 2.00M | 3.40M | 3.52M | 13.0M | 1.04M | 2.31M | 656.3K | 1.15M | 95.4K |
| Receivables | 1.00K | 69.0K | 174.0K | 107.0K | 92.0K | 52.0K | 13.0K | 13.8K | 19.2K | 30.4K |
| Inventory | 0 | 319.0K | 756.0K | 863.0K | 429.0K | 241.0K | 475.0K | 6.47K | ||
| Current assets | 13.0M | 2.64M | 4.65M | 5.31M | 14.3M | 1.50M | 2.97M | 675.8K | 1.18M | 134.8K |
| Property, plant and equipment | 12.6M | 2.00K | 122.0K | 12.0K | 11.0K | |||||
| Goodwill | 3.46M | 0 | ||||||||
| Total assets | 31.6M | 2.81M | 5.16M | 5.88M | 15.0M | 1.53M | 3.02M | 675.8K | 1.18M | 134.8K |
| Accounts payable | 264.0K | 125.0K | 713.0K | 1.32M | 789.0K | 370.0K | 369.0K | |||
| Current liabilities | 646.0K | 272.0K | 1.40M | 1.88M | 1.22M | 1.27M | 653.0K | 353.5K | 800.6K | 653.0K |
| Long-term debt | 6.45M | |||||||||
| Total debt | 6.45M | 369.0K | 530.0K | 708.0K | 1.47M | |||||
| Total liabilities | 7.44M | 272.0K | 1.58M | 2.25M | 1.76M | 2.71M | 653.0K | 353.5K | 800.6K | 653.0K |
| Shareholders' equity | 16.8M | 2.54M | 3.58M | 3.63M | 13.3M | -1.18M | 2.37M | 322.3K | 374.4K | -518.2K |
| Shares outstanding | 2.53M | 556.9K | 86.2K | 96.8K | 9.72M | 5.45K | 5.45K | 23.1M | 13.6M | 7.54M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -7.00M | -5.72M | -8.51M | -8.92M | -5.61M | -3.03M | -3.67M | -2.89M | -1.38M | -1.69M |
| Capital spending | -38.0K | 0 | -118.0K | -11.0K | 0 | 0 | -31.0K | 0 | 0 | 0 |
| Free cash flow | -7.04M | -5.72M | -8.63M | -8.93M | -5.61M | -3.03M | -3.70M | -2.89M | -1.38M | -1.69M |
| Cash from investing | -705.0K | 0 | -118.0K | -11.0K | -31.0K | |||||
| Cash from financing | 18.3M | 4.33M | 8.51M | -528.0K | 17.5M | 1.76M | 5.55M | 2.39M | 2.44M | 1.39M |
| Change in cash | 10.6M | -1.39M | -122.0K | -9.46M | 11.9M | -1.27M | 2.31M | -496.5K | 1.06M | -294.3K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 16, 2026 | Management or board change | SEC |
| NT 10-Q · Late filing notice | Nov 16, 2026 | Explanation request | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 12, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 9, 2026 | Material contract | SEC |
| 8-K · Current report | Nov 5, 2026 | Management or board change | SEC |
| 8-K · Current report | Nov 2, 2026 | Management or board change | SEC |
| 8-K · Current report | Oct 29, 2026 | Current report | SEC |
| 8-K · Current report | Oct 27, 2026 | Material contract | SEC |
| 8-K · Current report | Oct 26, 2026 | Current report | SEC |
| 8-K · Current report | Oct 22, 2026 | Current report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| EFFECT · Notice that a registration is effective | Oct 21, 2026 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Oct 21, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Oct 20, 2026 | Offer document | SEC |
| S-3 · Registration statement | Oct 16, 2026 | Offer document | SEC |
| DEF 14A · Proxy statement | Oct 16, 2026 | Meeting notice | SEC |
| 8-K · Current report | Oct 15, 2026 | Current report | SEC |
| 8-K · Current report | Oct 14, 2026 | Current report | SEC |
| 8-K · Current report | Oct 8, 2026 | Material contract | SEC |
| S-3 · Registration statement | Oct 7, 2026 | Offer document | SEC |
| 8-K · Current report | Oct 6, 2026 | Current report | SEC |
| DRS · Draft registration statement | Oct 5, 2026 | Offer document | SEC |
| PRE 14A · Preliminary proxy statement | Oct 5, 2026 | Meeting notice | SEC |
| 8-K · Current report | Oct 1, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 24, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 23, 2026 | Management or board change | SEC |
| 3 · Initial statement of ownership | Sep 17, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 17, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Sep 4, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 3, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 2, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Sep 1, 2026 | Material contract | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 27, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 27, 2026 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 24, 2026 | Big-stake notice | SEC |
| RW · Request to withdraw a registration | Aug 24, 2026 | Other filings | SEC |
| 8-K/A · Current report, amended | Aug 20, 2026 | Meeting outcome | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 19, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 17, 2026 | Management or board change | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | Aug 13, 2026 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 11, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 6, 2026 | Material contract | SEC |
| SCHEDULE 13D · Big-stake notice | Aug 3, 2026 | Big-stake notice | SEC |
| DEF 14A · Proxy statement | Jul 17, 2026 | Meeting notice | SEC |
| S-1 · Registration statement | Jul 17, 2026 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 17, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 14, 2026 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Jul 7, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 18, 2026 | Financing | SEC |
| S-8 · Registration statement for employee plans | Jun 5, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Jun 5, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 3, 2026 | Management or board change | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 8, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 4, 2026 | Insider trade | SEC |
| 8-K · Current report | May 4, 2026 | Management or board change | SEC |
| ARS · Annual report to shareholders | Apr 30, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 30, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 23, 2026 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Apr 20, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 20, 2026 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Apr 16, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Apr 15, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Apr 13, 2026 | Other filings | SEC |
| DRS · Draft registration statement | Apr 13, 2026 | Offer document | SEC |
| S-1 · Registration statement | Apr 13, 2026 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Apr 9, 2026 | Other filings | SEC |
| DRS · Draft registration statement | Apr 6, 2026 | Offer document | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 10-K · Annual report | Mar 30, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 25, 2026 | Results | SEC |
| 8-K · Current report | Mar 20, 2026 | Current report | SEC |
| 4 · Change in ownership | Mar 19, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 13, 2026 | Material contract | SEC |
| 8-K · Current report | Mar 11, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Mar 4, 2026 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 27, 2026 | Big-stake notice | SEC |
| 8-K/A · Current report, amended | Feb 23, 2026 | Current report | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| DEFA14A · Additional proxy material | Feb 9, 2026 | Meeting notice | SEC |
| 8-K · Current report | Feb 9, 2026 | Material contract | SEC |
| 424B3 · Prospectus | Jan 20, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Jan 20, 2026 | Offer document | SEC |
| 8-K · Current report | Jan 20, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Jan 20, 2026 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Jan 20, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 14, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 14, 2026 | Other filings | SEC |
| DEF 14A · Proxy statement | Jan 9, 2026 | Meeting notice | SEC |
| UPLOAD · Letter from the SEC | Jan 5, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 5, 2026 | Other filings | SEC |
| D | Dec 29, 2025 | Other filings | SEC |
| D | Dec 29, 2025 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | Dec 29, 2025 | Meeting notice | SEC |
| S-3 · Registration statement | Dec 29, 2025 | Offer document | SEC |
| S-3 · Registration statement | Dec 29, 2025 | Offer document | SEC |
| 4 · Change in ownership | Dec 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 22, 2025 | Insider trade | SEC |
| 424B3 · Prospectus | Dec 12, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Dec 12, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 11, 2025 | Acquisition or disposal | SEC |
| 8-K · Current report | Nov 18, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2025 | Results | SEC |
| 8-K · Current report | Nov 13, 2025 | Current report | SEC |
| 424B3 · Prospectus | Nov 6, 2025 | Offer document | SEC |
| S-3 · Registration statement | Oct 17, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 15, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Sep 24, 2025 | Insider trade | SEC |
| 1-A-W | Sep 17, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Sep 8, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Sep 5, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Sep 3, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 3, 2025 | Other filings | SEC |
| S-3 · Registration statement | Aug 29, 2025 | Offer document | SEC |
| 8-K · Current report | Aug 27, 2025 | Current report | SEC |
| 4/A · Change in ownership, amended | Aug 22, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Aug 22, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Aug 22, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 20, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2025 | Results | SEC |
| EFFECT · Notice that a registration is effective | Aug 13, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Aug 13, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Aug 12, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Aug 12, 2025 | Offer document | SEC |
| 4 · Change in ownership | Aug 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2025 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Aug 8, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 8, 2025 | Other filings | SEC |
| S-3 · Registration statement | Aug 8, 2025 | Offer document | SEC |
| S-3 · Registration statement | Aug 8, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Aug 5, 2025 | Other filings | SEC |
| DRS · Draft registration statement | Aug 4, 2025 | Offer document | SEC |
| DRSLTR · Letter to the SEC with a draft | Aug 4, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 31, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Jul 31, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Jul 30, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jul 28, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 25, 2025 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jul 25, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Jul 25, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Jul 25, 2025 | Offer document | SEC |
| DRS · Draft registration statement | Jul 25, 2025 | Offer document | SEC |
| 8-K/A · Current report, amended | Jul 25, 2025 | Material contract | SEC |
| UPLOAD · Letter from the SEC | Jul 9, 2025 | Other filings | SEC |
| 8-K · Current report | Jul 7, 2025 | Management or board change | SEC |
| CORRESP · Letter to the SEC | Jun 26, 2025 | Other filings | SEC |
| 8-K · Current report | Jun 25, 2025 | Material contract | SEC |
| 8-K · Current report | Jun 25, 2025 | Current report | SEC |
| UPLOAD · Letter from the SEC | Jun 17, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 6, 2025 | Other filings | SEC |
| S-1 · Registration statement | Jun 6, 2025 | Offer document | SEC |
| ARS · Annual report to shareholders | Jun 2, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Jun 2, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | May 23, 2025 | Meeting notice | SEC |
| 8-K · Current report | May 22, 2025 | Current report | SEC |
| UPLOAD · Letter from the SEC | May 21, 2025 | Other filings | SEC |
| 8-K · Current report | May 20, 2025 | Current report | SEC |
| DRS · Draft registration statement | May 15, 2025 | Offer document | SEC |
| DRSLTR · Letter to the SEC with a draft | May 15, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2025 | Results | SEC |
| 8-K · Current report | May 14, 2025 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | May 14, 2025 | Other filings | SEC |
| 424B3 · Prospectus | May 13, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | May 9, 2025 | Other filings | SEC |
| S-1 · Registration statement | May 9, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | May 8, 2025 | Other filings | SEC |
| DRS · Draft registration statement | May 2, 2025 | Offer document | SEC |
| DRSLTR · Letter to the SEC with a draft | May 2, 2025 | Other filings | SEC |
| 8-K · Current report | May 2, 2025 | Material contract | SEC |
| 8-K · Current report | Apr 22, 2025 | Current report | SEC |
| 8-K · Current report | Apr 14, 2025 | Current report | SEC |
| 424B5 · Prospectus | Apr 14, 2025 | Offer document | SEC |
| 8-K · Current report | Apr 10, 2025 | Current report | SEC |
| 8-K · Current report | Apr 3, 2025 | Financing | SEC |
| 10-K · Annual report | Mar 21, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 21, 2025 | Results | SEC |
| 8-K · Current report | Mar 6, 2025 | Current report | SEC |
| 8-K · Current report | Mar 5, 2025 | Current report | SEC |
| 4 · Change in ownership | Feb 24, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 24, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 24, 2025 | Management or board change | SEC |
| 8-K · Current report | Feb 12, 2025 | Material contract | SEC |
| 8-K · Current report | Feb 5, 2025 | Meeting outcome | SEC |
| DEF 14A · Proxy statement | Jan 3, 2025 | Meeting notice | SEC |
| 8-K · Current report | Jan 3, 2025 | Current report | SEC |
| 8-K · Current report | Dec 23, 2024 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Dec 23, 2024 | Meeting notice | SEC |
This page holds 200 of 407 filings. Open Filings
Cap table
Built by 6ix from Valion Bio, Inc.’s releases
- Common shares
- 2,155,637
- Fully diluted
- 2,155,637
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 2,155,637 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 2,155,637 |
| Aug 27, 2026 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Christina Valauri Other companies: Precipio, Inc. (Director · Since at least Jan 2, 2024) | Director · Since at least Jul 1, 2024 |
| Lisa Wolf Other companies: Resonant Inc (Chief Accounting Officer · May 14, 2021 – Mar 28, 2022 · Past) | Chief Operating Officer & Chief Financial Officer · Since at least Oct 1, 2024 |
| Thomas Jensen Other companies: Allarity Therapeutics, Inc. (CEO · Since at least Dec 20, 2021) | Director · Since at least Aug 27, 2026 |
| Anna Szymanska | SVP, Quality and Regulatory Compliance · Since at least Nov 20, 2026 |
| Blake Gurfein | Chief Scientific Officer · Nov 10, 2021 – Dec 18, 2024 · Past |
| Briana Benz | Chief Financial Officer · Nov 10, 2021 – Nov 10, 2021 · Past |
| Brian W. O'Mara | VP, Process Sciences and Manufacturing · Since at least Nov 20, 2026 |
| Dean Zikria | Interim CEO, Director · Since at least Aug 6, 2025 |
| Jared Malbin | Director · Since at least Aug 27, 2026 |
| Jennifer Ernst | Chief Executive Officer, Director · Since at least Nov 10, 2021 |
All 12 people
| Person | Seat |
|---|---|
| Melinda Lackey | General Counsel and SVP of Legal · Since at least May 4, 2026 |
| Michael K. Handley | Director · Since at least Aug 6, 2025 |
Log in to ask 6ix AI your own questions about Valion Bio, Inc.